Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

First clinical results for CFI-400945 show signs of activity in patients with solid tumors

May 6, 2016

TEASE: early phase II data for ALK-001

May 6, 2016

Anti-c-Met antibody-drug conjugate from Sorrento to enter IND-enabling studies

May 6, 2016

CLG-561 for AMD

May 6, 2016

NicOx's NO-donating travoprost derivative in models of ocular hypertension

May 6, 2016

Phase I/IIa study results for Parion Sciences' P-321 in dry eye disease

May 5, 2016

Phase I data for Isarna Therapeutics' ISTH-0036 in glaucoma

May 5, 2016

Blueprint Medicines develops potent and selective RET inhibitors for cancer

May 5, 2016

ROS1 inhibitor DS-6051 well tolerated in first-in-human study

May 5, 2016

Bayer describes novel radioimmunoconjugate BAY-1862864 entering phase I development

May 4, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.